Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.46 |
| ▸ | CHRNA2 | Q15822 | 3/20 | 0.46 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6915041 | 1.00 | CHRM1 (0.54) | CHRM1CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6911868 | 0.78 | CHRM1 (0.51) | CHRM1 | |
| SCHEMBL12996851 | 0.74 | SMN1; SMN2 (0.46) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA2 | |
| SCHEMBL8076754 | 0.74 | CHRM1 (0.85) | CHRM1CHRNB2CHRNA4 | |
| SCHEMBL6911863 | 0.73 | CHRNB2 (0.55) | CHRM1CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL6917336 | 0.70 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL23133816 | 0.70 | SMN1; SMN2 (0.44) | CHRNB2CHRNA4 | |
| SCHEMBL24805404 | 0.70 | ALDH1A1 (0.46) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA2 | |
| SCHEMBL6912925 | 0.69 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL13610210 | 0.68 | ALDH1A1 (0.49) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | claimed |
| EP-0874828-A4 | COMPOSITION FOR TREATING PAIN | LILLY CO ELI (US) | 1999-09-01 | — | — | EP | claimed |
| EP-0874828-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | claimed |
| US-5665745-A | 1,2,5-THIADIAZOLE DERIVATIVES FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | claimed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | claimed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | claimed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| US-20040023951-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY | 2004-02-05 | — | — | US | disclosed |
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0874828-A4 | COMPOSITION FOR TREATING PAIN | LILLY CO ELI (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5929247-A | METHODS OF SYNTHESIZING 1,2,5-THIADIAZOLE COMPOUNDS SUCH AS 3-PROPYLTHIO-4-HYDROXY-1,2,5-THIADIAZOLE, USEFUL IN TREATING DISEASES IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MUSCARINIC CHOLINERGIC SYSTEM MALFUNCTIONING | ELI LILLY AND COMPANY (US) | 1999-07-27 | — | — | US | disclosed |
| US-5852037-A | Method for treating anxiety | ELI LILLY AND COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0874828-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5672709-A | INTERMEDIATES FOR DRUGS USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| US-5665745-A | 1,2,5-THIADIAZOLE DERIVATIVES FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | ELI LILLY AND COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| US-5646289-A | REACTING A 3-CHLORO-1,2,5-THIADIAZOLE WITH ALKALI METAL BIS(TRIALKYL OR ARYLSILYL)AMIDE; DECHLORINATION; TREATING NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997017962-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023951-A1 | Combination therapy for treatment of psychoses | CHRM5, CHRM4, CHRM2 | CHRM1 8/4885CHRNB2 16/4885CHRNA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.